KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
Kyverna Therapeutics Inc KYTX
$6.84
▲ +0.29%
(+$0.02)
🔥 High Short Interest
Open
$6.83
Prev Close
$6.82
Day Range
$6.75 – $6.95
52W Range
$5.30 – $13.67
Market Cap
$423.01M
Beta
2.09
EPS (TTM)
$-2.94
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-02-08 |
| Shares Out. | 60,800,000 |
| Website | kyvernatx.com/ ↗ |
| Phone | 15106268331 |
| Employees | 149 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$38.3M |
| Free Cash Flow | -$159.0M |
| Total Assets | $219.8M |
| Total Liabilities | $54.3M |
| Equity | $165.5M |
About Kyverna Therapeutics Inc
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Kyverna Therapeutics Inc is a publicly traded company under the ticker symbol KYTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)
📰 Latest News for KYTX
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow
Kyverna stock jumps on positive one-year therapy data
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct